News releases

Stay up to date on our latest developments and company news

Basking Biosciences Announces First Participants Dosed in Phase 1 Study of BB-025, a Direct-Acting Reversal Agent for Investigational Stroke Therapy BB-031

First clinical evaluation of BB-025, designed to rapidly and specifically reverse BB-031 activity, advancing Basking's goal to redefine thrombosis treatment

November 12, 2025

Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer

Financing supports execution of Phase 2b RAISE trial evaluating BB-031, an investigational reversible thrombolytic for acute ischemic stroke, and the planned Phase 1 study of BB-025, its fast-acting reversal agent / Current CEO Richard Shea transitions to President and Chief Operating Officer

October 22, 2025

Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke

Novel RNA aptamer designed to inhibit the function of von Willebrand Factor and promote thrombolysis

September 10, 2025

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Financing will fund upcoming Phase 2 trial of BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF) in development to treat acute ischemic stroke / Financing was led by ARCH Venture Partners

January 30, 2024

Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference

Phase 2-Ready Drug Candidate Offers Potential to Greatly Broaden the Acute Ischemic Stroke Population Who Can Benefit from Thrombolytic Therapy

May 9, 2023

Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023

BB-031, a potential rapid onset, short-acting and reversible thrombolytic, targets von Willebrand Factor, a key structural component of thrombi and driver of blood clotting / Company to initiate a Phase 2 clinical proof-of-concept study of BB-031 in patients with acute ischemic stroke

February 9, 2023

Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023

The clinical-stage biopharmaceutical company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate

January 31, 2023

Basking Biosciences, Inc. Completes $5.4M Seed Financing

Funding to support development of the first reversible thrombolytic therapy for acute ischemic stroke

December 7, 2020

view all

Media Contact

For media inquiries or interview requests, please get in touch.

media@baskingbiosciences.com